The Q3 2016 earnings call for Merck & Co., Inc. highlights several positive and strategic developments that are likely to have a favorable impact on the company's stock price in the short term.

### Key Positives:
- **Strong Performance and Guidance**: Merck reported solid sales and earnings growth, with total company revenues increasing by 5% year-over-year. The company narrowed and raised its full-year revenue and EPS guidance, indicating confidence in its performance[5%.
- **KEYTRUDA Success**: The FDA approval of KEYTRUDA for first-line treatment of metastatic lung cancer, along with expanded labeling and strong clinical trial results, positions KEYTRUDA as a leader in the oncology market. This is expected to drive significant growth and adoption[5].
- **Other Pipeline Advancements**: Merck highlighted progress in other pipeline assets, including ZINPLAVA, letermovir, and doravirine, which contribute to a robust and diversified pipeline[5].
- **Business Development**: The company remains committed to business development, seeking opportunities to augment its pipeline, which could lead to further growth and innovation[5].

### Short-Term Implications:
- The immediate impact of these positive developments, particularly the KEYTRUDA approvals and the strong financial performance, is likely to be positive on the stock price.
- The guidance adjustments and the ongoing investment in high-potential programs like KEYTRUDA and ZEPATIER suggest a strong outlook for the company.
- While there are challenges ahead, such as the loss of market exclusivity for ZETIA and VYTORIN, the company's strategic focus and pipeline strengths are expected to mitigate these impacts in the short term.

Given these factors, the stock is likely to experience a positive impact in the short term.

[2]